Skip to content

Issues: broadinstitute/profiling-resistance-mechanisms

New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Sign up for GitHub

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

27 Open 24 Closed
27 Open 24 Closed
Author
Filter by author
Loading
Label
Filter by label
Loading
Use alt + click/return to exclude labels
or ⇧ + click/return for logical OR
Projects
Filter by project
Loading
Milestones
Filter by milestone
Loading
Assignee
Filter by who’s assigned
Sort
Sort by
Newest Oldest Most commented Least commented Recently updated Least recently updated Best match
Most reactions
👍 👎 😄 🎉 😕 ❤️ 🚀 👀

Issues list

Image dsplay on the landing page are broken
#134 opened Dec 15, 2023 by braymp
Investigate Bortezomib signature in the context of other proteasomal inhibitors
#127 opened Jul 5, 2023 by shntnu
@yhan8
5
CellProfiler feature analysis Discussion and Notes Documenting ideas/discussions Experiments Tracking experimental questions, results, or analysis
#119 opened Sep 29, 2021 by gwaybio
29
Enhancement of 3.resistance-signature/0.training-test-split.ipynb
#116 opened Sep 15, 2021 by yhan8
Remaining analyses before writing the paper Discussion and Notes Documenting ideas/discussions Experiments Tracking experimental questions, results, or analysis
#112 opened Aug 19, 2021 by gwaybio
2
Notes from Meeting 12/9/20
#92 opened Dec 8, 2020 by shntnu
Batch 9 and 10 Data Summary Data Data additions or descriptions
#89 opened Nov 6, 2020 by gwaybio
Bulk signature analysis Discussion and Notes Documenting ideas/discussions Experiments Tracking experimental questions, results, or analysis
#83 opened Sep 18, 2020 by gwaybio
5
Adding CellProfiler Pipelines
#80 opened Aug 20, 2020 by gwaybio
Single Cell Analysis Results Data Data additions or descriptions Google Slides Publicly viewable slides within
#78 opened Aug 10, 2020 by gwaybio
Experiment Design - New Drugs Data Data additions or descriptions Discussion and Notes Documenting ideas/discussions
#76 opened Aug 6, 2020 by gwaybio
4
Increase Interpretability of Signature Interpretation Figure
#68 opened Apr 28, 2020 by gwaybio
1
Signature Analysis - PMSB5 and generic resistance signatures Discussion and Notes Documenting ideas/discussions Experiments Tracking experimental questions, results, or analysis
#58 opened Mar 17, 2020 by gwaybio
5
Migrate UMAP in 3.feature-differences to 2.describe data enhancement New feature or request
#54 opened Mar 11, 2020 by gwaybio
Comparing Multiple Clones to Clone A and E Discussion and Notes Documenting ideas/discussions
#53 opened Mar 11, 2020 by gwaybio
We no longer observe four clear "groups" in batch 3 data Discussion and Notes Documenting ideas/discussions Experiments Tracking experimental questions, results, or analysis
#51 opened Mar 10, 2020 by gwaybio
1
Correlate Mechanisms of Resistance with Morphology Profiles Experiments Tracking experimental questions, results, or analysis
#49 opened Mar 3, 2020 by gwaybio
5
Notes from Meeting 1/21/20 Discussion and Notes Documenting ideas/discussions
#47 opened Jan 28, 2020 by gwaybio
1
Notes from Meeting 1/8/20 Discussion and Notes Documenting ideas/discussions
#46 opened Jan 13, 2020 by gwaybio
2
Cloning Details Discussion and Notes Documenting ideas/discussions
#45 opened Jan 8, 2020 by gwaybio
2
Data Summary 2019 Data Data additions or descriptions
#40 opened Dec 19, 2019 by gwaybio
5
Refactor Repository
#37 opened Dec 2, 2019 by gwaybio
1
Notes from Meeting 11/13/19 Discussion and Notes Documenting ideas/discussions
#35 opened Nov 13, 2019 by gwaybio
Compile list of top 10 or so morphology features indicative of resistance mechanism Discussion and Notes Documenting ideas/discussions
#34 opened Nov 13, 2019 by gwaybio
Add Cell Count to SubCluster Morpheus Heatmap
#33 opened Nov 13, 2019 by gwaybio
ProTip! no:milestone will show everything without a milestone.